Objective: Patients with a gastrointestinal stromal tumour (GIST) suffering from non-islet cell tumour-induced hypoglycaemia (NICTH), being associated with increased plasma levels of pro-insulin-like growth factor (IGF)-IIE , have been reported occasionally. We studied the clinical relevance of pro-IGF-IIE and other IGF-related proteins in GIST patients.
introduction
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal malignant tumours of the gastrointestinal tract. GISTs are characterised by the overexpression of the receptor tyrosine kinase KIT. In 80% of the GISTs, KIT gain-of-function mutations are found, while 5%-7% of the tumours harbour platelet-derived growth factor receptor a (PDGFRA)-activating mutations [1] . Patients with metastatic or unresectable GIST are successfully treated with imatinib, an inhibitor of KIT and PDGFRA [2] .
Non-islet cell tumour-induced hypoglycaemia (NICTH) is a paraneoplastic syndrome characterised by recurrent fasting hypoglycaemia. It is associated with the secretion of incompletely processed precursors of insulin-like growth factor (IGF)-II by the tumour into the circulation. These precursors consist mainly of mature IGF-II with a 21-residue carboxyl extension of the E-domain of pro-IGF-II, called pro-IGF-IIE or 'big'-IGF-II (for review, see [3] ). Patients with NICTH usually exhibit low circulating levels of insulin-like growth factor-binding protein (IGFBP)-3 and total IGF-I, whereas those of IGFBP-2 (occasionally) IGFBP-6 and free unbound IGFs are increased [3, 4] .
Recently, we and others have reported on the occurrence of NICTH in patients with a GIST [5] [6] [7] [8] [9] [10] . Based on these relatively high number of cases reported so far, it seems that patients with a GIST are at risk for developing NICTH. In the present study, we determined the plasma levels of IGF-I, total IGF-II, pro-IGF-IIE[68-88], IGFBP-2, -3 and -6 for a cohort of patients with a GIST, before and during treatment with imatinib. The predictive values of these parameters with respect to the occurrence of hypoglycaemia, disease progression and response on treatment were evaluated.
patients and methods patients
Twenty-four consecutive newly treated patients at the department of Medical Oncology of the University Medical Center Groningen were included in this study. Patients were eligible in case of advanced unresectable or metastatic histologically proven GIST, as characterised by CD117 positivity, for which treatment with imatinib was indicated. Every patient underwent a routine computed tomography (CT) scan before the start of therapy, 8 weeks after start of therapy and every 3 months thereafter until progression of disease. In addition, routine 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) scanning was carried out a few days before and 1 week after the start of imatinib. EDTA-plasma samples were collected before the start of treatment, 1 week after start of therapy and during the first year (median 5 months, range 2-12 months) of treatment. For those patients who developed hypoglycaemia during clinical follow-up, routine, non-fasting, EDTA-plasma samples were taken to diagnose NICTH.
Overall tumour size was determined by the sum of the longest diameter for all target lesions as defined by RECIST [11] . Initial overall response to therapy was defined when at least two of the following events were noted in an individual patient: (i) improvement of clinical symptoms, (ii) CT scan response (partial response according to RECIST, i.e. ‡30% decrease in the sum of the longest diameter of target lesions based on CT before and 8 weeks after start of treatment [11] ) or (iii) >25% decrease in FDG uptake on PET scanning on day 8 compared with the pretreatment scan [12, 13] . The examination of the PET images was carried out as described previously by using standardised uptake value analysis [14] . Disease progression after initial response was defined as (i) the occurrence of a new lesion, (ii) increasing size of the pre-existing lesions (as defined by RECIST) or (iii) development of an intratumoral nodule and/or an increase in 'solid' tissue, in the background of a hypodense lesion [13] .
The study protocol was approved by the Medical Ethics Committee of the University Medical Center Groningen and all patients gave their informed consent.
measurement of plasma levels of IGFs and IGFBPs
Concentrations of IGFBP-2, IGFBP-3, IGFBP-6, IGF-I, pro-IGF-IIE[68-88] and total IGF-II (i.e. both mature 7.4 kDa IGF-II and pro-IGF-IIE are detected in this radioimmunoassay with nearly equal potency) in plasma and cyst fluid were determined as described previously [15] [16] [17] .
cyst fluid, GIST specimens and histological examinations For two patients cyst fluid was aspirated from metastatic lesions using a routine procedure to relieve abdominal tension.
From 17 of 24 patients paraffin-embedded tumour samples were available. From each tumour sample, three (distinct) representative 0.6-mm cores were taken and transferred to a standard-size recipient paraffin block and immunohistochemistry was carried out as described previously [18] . Antigen retrieval was carried out by boiling slides in 0.01 M citrate buffer (pH 6.0). Primary antibodies were rabbit anti-IIE[68-88] antiserum (1 : 200; WKZ6279) [16] and polyclonal goat anti-IGFBP-2 (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA). As a negative control, a serial section was processed by replacement of primary antibody with preimmune primary antisera or normal goat IgG. The methods used for in situ hybridisation with digoxigenin-labelled hIGF-II complementary RNA probes have been described previously [19] . Negative controls for in situ hybridisation were prepared using sense probes. For both immunohistochemistry and in situ hybridisation, normal tissue samples derived from first trimester placenta served as positive controls [20] . The intensity of histochemical staining was evaluated by two independent observers (BR and AJHS). Tissue cores from a particular tumour were judged to be positive when there was a clear cytoplasmic staining in at least two of the three cores.
Tumours from patients with NICTH were analysed for KIT and PDGFRA mutations as described in the supplementary materials and methods section and the supplementary table (available at Annals of Oncology online).
statistics
As the plasma levels of most of the IGFs and IGFBPs are age and sex dependent, the concentrations were compared with age-and sex-dependent references and expressed as standard deviation scores (SDS) [15] [16] [17] . The Wilcoxon signed rank test was used to compare plasma levels with the reference population or to analyse paired data. Differences between two groups were studied with the Mann-Whitney U test. Correlations were described by the Spearman's rank correlation coefficient (r). The log-rank test was applied to analyse the impact of variables on survival. A doublesided P value <0.05 was considered statistically significant using SPSS for windows version 12.0.
results general clinical characteristics of the GIST patients
Patient characteristics are summarised in Table 1 . Two-thirds of the patients had metastatic disease and the median total tumour size was 14 cm. The initial overall response to imatinib was 75% with a median progression-free survival of 25 months which is in agreement with previous reports [2] . Three patients encountered episodes of symptomatic hypoglycaemia, with fasting plasma glucose levels <3.0 mmol/l, either during treatment with a tyrosine kinase inhibitor or in the course of follow-up after treatment. These patients will be presented in more detail in the last paragraph.
pretreatment plasma levels of IGFs and IGFBPs
Pretreatment plasma samples were available from 22 of 24 patients included in this study. The median SDS values of the IGFs and IGFBPs, as determined before imatinib treatment, are shown in Table 2 . Eight patients (36%) showed plasma pro-IGF-IIE[68-88] levels >1.0 SDS, including one patient with a plasma level >2.0 SDS. This patient developed NICTH. The median concentration of IGFBP-2 in the plasma of GIST patients was markedly higher than that observed in healthy individuals. For 14 patients (64%), the plasma IGFBP-2 levels exceeded 2.0 SDS. In contrast, the median IGFBP-3 SDS for GIST patients was slightly but significantly reduced compared with the reference population.
Patients with a relatively high tumour load (i.e. total diameter >12 cm [21] ) exhibited significantly higher pretreatment plasma levels of pro-IGF-IIE[68-88] than subjects with a lower tumour load. Furthermore, plasma levels of pro-IGF-IIE[68-88] were higher in patients with metastatic disease than those with single primary (unresectable) tumours. In addition, we encountered that increased serum lactate dehydrogenase (LDH) (i.e. >235 U/l) predicted a relatively high plasma pro-IGF-IIE[68-88] level (Table 3) . Serum LDH correlated well with total tumour size (r = 0.848, P < 0.001). We found a significant inverse correlation between serum albumin levels and plasma IGFBP-2 SDS values (r = 20.559, P = 0.007). No associations were found between IGF-I, total IGF-II, IGFBP-3 and IGFBP-6 plasma levels and any of the clinical parameters studied. Elevated plasma levels (i.e. either SDS >1.0 or >2.0) of any component of the IGF system investigated did not predict progression-free survival. In addition, we analysed the mutual relationships among the pretreatment levels of IGFs and IGFBPs. IGF-I SDS correlated with total IGF-II SDS and IGFBP-3 SDS (r = 0.521, P = 0.013 and r = 0.475, P = 0.025, respectively). Total IGF-II SDS correlated negatively with IGFBP-2 SDS (r = -0.562, P = 0.007).
plasma levels of IGFs and IGFBPs in patients during treatment with imatinib
In the total group of patients, the plasma SDS values of the various IGFs and IGFBPs did not change significantly after 1 Cross-sectional analysis revealed that, during the first year of treatment, the plasma IGFBP-2 levels in patients with progressive disease were significantly higher compared with those in patients without progressive disease (Table 4) . Within the first treatment year, two additional patients (besides the one who already showed a high pretreatment value) had plasma pro-IGF-IIE[68-88] levels that exceeded 2.0 SDS and subsequently also developed NICTH (Table 5) .
IGF-II and IGFBP-2 in GIST specimens and tumour cyst fluid
Sixteen of the 17 (94%) tumours studied showed significant IGF-II mRNA expression. Fourteen of the mRNA-positive samples stained also positive for IIE[68-88]-containing peptides. The GIST specimens of the patients with hypoglycaemia, who exhibited elevated pro-IGF-IIE[68-88] plasma levels, showed a pronounced expression of both IGF-II mRNA and protein (Supplemental Figure 1 , available at Annals of Oncology online). In contrast, positive staining for IGFBP-2 protein was observed for only one GIST. Curiously, the patient from whom this tumour specimen was obtained showed only moderately elevated plasma IGFBP-2 levels (2.09 SDS). Analysis of cyst fluid revealed that the concentrations of pro-IGF-IIE[68-88] in cyst fluid and the corresponding plasma sample were nearly similar, i.e. 6.9 and 7.3 nmol/l (=0.3 SDS), respectively, in one case. For the second patient, who exhibited an elevated level of pro-IGF-IIE[68-88] in plasma (14.5 nmol/l, corresponding to 3.5 SDS), the molar ratio of pro-IGF-IIE[68-88] between cyst fluid and plasma was markedly higher, i.e. 1.6. For the two patients investigated, molar ratios of IGFBP-2 between cyst fluid and plasma were 1.1 and 0.8.
patients with NICTH
The first patient was a 50-year-old man and has been described previously [6] . In short, this patient had a large recurrent retroperitoneal GIST with a KIT exon 9 mutation. After an initial response to imatinib, he suffered from progressive disease and developed a hypoglycaemic coma. The second patient was an 83-year-old woman with type 2 diabetes mellitus treated with insulin and a recurrent unresectable GIST with a KIT exon 9 mutation. During imatinib treatment, her daily insulin doses had to be reduced continuously to maintain acceptable glucose levels. After 3 years of imatinib treatment, she had disease progression, switched to sunitinib and developed nocturnal episodes of hypoglycaemia, without insulin treatment. She died comatose at home while having progressive disease. The third patient was an 82-year-old woman with liver metastases from a gastric tumour with a PDGFRA exon 18 (Asp842Val) mutation. She did not respond to imatinib and developed fasting hypoglycaemias 8 weeks after the start of the treatment. At the time hypoglycaemia became manifest, markedly elevated plasma levels of both pro-IGF-IIE[68-88] and IGFBP-2 and low concentrations of IGFBP-3 and IGF-I were observed in all patients (Table 5) . Patient 2 showed a plasma IGFBP-6 level that exceeded 2.0 SDS, a phenomenon that has been encountered previously for some patients suffering from NICTH [22] . Notably, patient 3 showed a strikingly elevated concentration of pro-IGF-IIE[68-88] already before and 1 week after the start of imatinib ( It appeared that at any moment before or during treatment, 11 of the 24 (46%) patients studied exhibited pro-IGF-IIE[68-88] levels that were >1.0 SDS. Three of these patients showed values of pro-IGF-IIE[68-88] that even exceeded 2.0 SDS. Later on, they developed hypoglycaemia. These findings and the various previous case reports on this subject [5, [7] [8] [9] [10] indicate that elevated plasma concentrations of pro-IGF-IIE are not uncommon in patients with a GIST and would predict a high risk for the development of hypoglycaemia. Histological examination and analysis of cyst fluid of the various GISTs revealed that it is highly likely that most of the pro-IGF-IIE[68-88] detected in plasma is secreted by tumour tissue. Indeed, a relatively high tumour mass and/or increased serum LDH appeared to be associated with significantly higher plasma levels of pro-IGF-IIE . In addition, our data indicate that metastatic GISTs tend to produce more pro-IGF-IIE . Presumably, when a certain threshold level of pro-IGF-IIE in the circulation has been exceeded, growth hormone secretion by the anterior pituitary gland will become reduced due to an increased feedback inhibition [3] . Moreover, the formation of 150-kDa IGF-IGFBP-3-acid-labile subunit complexes in the circulation is increasingly hampered. This cascade of events results in an increased insulin-like activity in the body that may ultimately overrule the various counter regulatory mechanisms for hypoglycaemia.
The three patients with hypoglycaemia reported in this study did not suffer from conditions such as (ad)renal failure, hepatic dysfunction or cachexia that could alternatively explain the occurrence of hypoglycaemia [23] . However, there are some reports that suggest that imatinib, and also the second-line tyrosine kinase inhibitor sunitinib, could influence glucose metabolism in patients with type 2 diabetes mellitus and possibly also in nondiabetic patients with a disturbed glucose homeostasis, like NICTH [8, 24, 25] . We also observed an improvement of fasting blood glucose levels in a patient with type 2 diabetes mellitus during treatment with imatinib and later on with sunitinib, which allowed a consequent reduction of her insulin dosage before she finally suffered from NICTH. The latter could have been facilitated by the use of a KIT kinase inhibitor as suggested by Hamberg et al. [8] .
Within our total patient population, we noticed that plasma IGFBP-3 levels, being already slightly reduced before treatment, declined further during prolonged imatinib therapy. Theoretically, this could increase the tissue availability of IGFs, including pro-IGF-IIE[68-88], facilitating the occurrence of hypoglycaemia and reducing insulin resistance in type 2 diabetes mellitus [26] . Recently, it was reported that IGFBP-3 mRNA was induced in GISTs that responded to imatinib according to FDG-PET several days after initiation of treatment. In contrast, IGFBP-3 mRNA was suppressed in nonresponding GISTs [27] . In our evaluation, however, we noticed no significant changes in IGFBP-3 plasma levels after 1 week of imatinib treatment, irrespective of the PET response (data not shown) suggesting that an eventual induction of IGFBP-3 mRNA and protein in responsive GISTs does not influence the plasma levels of this IGFBP.
Mutation analysis carried out on tumour tissues obtained from the three patients with NICTH revealed that two patients had a tumour with a KIT exon 9 mutation and one had a PDGFRA exon 18 mutation. These mutations have a much lower incidence (i.e. 10% and 6%, respectively) than those that affect KIT exon 11, being by far the most frequent mutation found in GISTs (60%) [1] . So far, only one NICTH GIST case with a KIT exon 9 mutation has been reported [9] . Interestingly, Braconi et al. recently reported that a decreased disease-free survival in patients with a GIST was independently associated with IGF-II expression by the tumour. In addition, they found that IGF-II was more frequently expressed in tumours with KIT exon 9 mutations than in those with other mutations suggesting that mutational status could influence IGF-II expression and possibly the occurrence of NICTH [28] .
In the majority of the patients, plasma IGFBP-2 levels were markedly elevated. Several studies have shown that circulating IGFBP-2 levels may be elevated in various malignancies [29] [30] [31] [32] [33] and may be associated with increasing tumour size, disease stage and adverse prognosis [29, 30, 32] . There were no such associations in our study, although patients with progressive diseases had significantly higher plasma levels of IGFBP-2 than patients who responded to imatinib. It has been suggested that elevated circulating IGFBP-2 levels found in patients with aforementioned malignancies are caused by the secretion of this protein by the tumour. However, our analysis of tissue and cyst fluid suggests that the elevated plasma levels of IGFBP-2, as found for most of the GIST patients, are due to other, systemic, original article Annals of Oncology
